

JCO Rec'd PCT/PTO 29 MAR 2002

FORM-PTO-1390 (Rev. 9-2001)		U S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 033285-009 U S APPLICATION NO (If known, see 37 C F R 1.5) UNASSIGNED
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>			10/089436
INTERNATIONAL APPLICATION NO. PCT/EP00/09391	INTERNATIONAL FILING DATE 26 SEPTEMBER 2000	PRIORITY DATE CLAIMED 30 SEPTEMBER 1999	
TITLE OF INVENTION NOVEL COMBINATION OF LOTEPREDNOL AND ANTIHISTAMINES			
APPLICANT(S) FOR DO/EO/US Istvan SZELENYI et al.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input checked="" type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input checked="" type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input checked="" type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11 to 20 below concern document(s) or information included:			
<p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information:</p>			
Verification of Translation of application into English; Form PCT/ISA/210 (Int'l. Search Report); Form PCT/IPEA/409 (w/2 amended sheets); Form PCT/IPEA/401; Form PCT/RO/101 (6 pgs.); Form PCT/IB/306; Form PCT/IB/301; Form PCT/IB/304; Form PCT/IB/308; Form PCT/IB/332; Verification of Translation of (2) Amended Sheets and Cover Page of WO 01/22955 A2.			



21839

1.05 089436  
1070 Rec'd PCT/PTO 29 MAR 2002

U.S. APPLICATION NO (If known, see 37 C F R 1 5) <b>UNASSIGNED</b>		INTERNATIONAL APPLICATION NO <b>PCT/EP00/09391</b>		ATTORNEY'S DOCKET NUMBER <b>033285-009</b>	
21. <input checked="" type="checkbox"/> The following fees are submitted:				<b>CALCULATIONS</b>	
<b>Basic National Fee (37 CFR 1.492(a)(1)-(5)):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO ..... \$1,040.00 (960) International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO ..... \$890.00 (970) International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$740.00 (958) International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$710.00 (956) International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$100.00 (962) <b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b>				\$ 890.00	
Surcharge of <b>\$130.00 (154)</b> for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492(e)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				\$	
Claims	Number Filed	Number Extra	Rate		
Total Claims	10 -20 =	0	X\$18.00 (966)	\$ 0.00	
Independent Claims	4 -3 =	1	X\$84.00 (964)	\$ 84.00	
Multiple dependent claim(s) (if applicable)			+ \$280.00 (968)	\$ 0.00	
<b>TOTAL OF ABOVE CALCULATIONS =</b>				\$ 84.00	
Reduction for 1/2 for filing by small entity, if applicable (see below).				+	\$ -
<b>SUBTOTAL =</b>				\$ 974.00	
Processing fee of <b>\$130.00 (156)</b> for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492(h)). 20 <input type="checkbox"/> 30 <input type="checkbox"/>				+	
<b>TOTAL NATIONAL FEE =</b>				\$ 974.00	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00 (581)</b> per property				+	\$
<b>TOTAL FEES ENCLOSED =</b>				\$ 974.00	
				Amount to be refunded:	\$
				charged:	\$
a. <input type="checkbox"/> Small entity status is hereby claimed.					
b. <input checked="" type="checkbox"/> A check in the amount of \$ <u>974.00</u> to cover the above fees is enclosed.					
c. <input type="checkbox"/> Please charge my Deposit Account No. <u>02-4800</u> in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed.					
d. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>02-4800</u> . A duplicate copy of this sheet is enclosed.					
<b>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</b>					
SEND ALL CORRESPONDENCE TO:					
Teresa Stanek Rea, Esquire BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620					
				SIGNATURE <b>TERESA STANEK REA</b>	
				NAME	
30,427				MARCH 29, 2002	
REGISTRATION NUMBER				DATE	

10/089436 #4/a  
JC10 Rec'd PCT/PTO 29 MAR 2002  
Patent  
Attorney's Docket No. 033285-009

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
Istvan SZELENYI <i>et al.</i>	)	Group Art Unit: Unassigned
	)	
Application No.: Unassigned	)	Examiner: Unassigned
(Corresponds to PCT/EP00/09391)	)	
	)	
Int'l. Filing Date: 26 September 2000	)	
	)	
For: NOVEL COMBINATION OF	)	
LOTEPREDNOL AND	)	
ANTIHISTAMINES	)	
	)	

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination, please amend the above-captioned application as follows:

**IN THE CLAIMS:**

Please cancel claim 10 without prejudice or disclaimer.

Kindly amend claims 1-9 and 11 as follows:

1. (Amended) A pharmaceutical composition comprising an effective amount of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine.
2. (Amended) The composition according to claim 1, wherein the antihistamine is a topically administrable antihistamine.

3. (Amended) The composition according to claim 1, wherein the antihistamine is azelastine and/or levocabastine.

4. (Amended) The composition according to claim 1, wherein the pharmaceutically tolerable ester is loteprednol etabonate.

5. (Amended) A method for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising administering to a patient in need thereof, an effective amount of loteprednol and at least one topically administrable antihistamine, optionally together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

6. (Amended) The method according to claim 5, wherein such administration is intranasally or intraocularly simultaneously, in succession or independently of one another.

7. (Amended) The method according to claim 5, which is administered as an inhalable liquid or solid preparation.

8. (Amended) The method according to claim 5, which is administered orally.

9. (Amended) A method for the treatment and prophylaxis of airway disorders and/or allergies, comprising administering to a patient in need thereof, an effective amount

of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine, wherein the loteprednol or a pharmaceutically tolerable ester thereof and the antihistamine(s) are mixed individually or together, optionally together with customary excipients or vehicles, and the mixture is in a suitable administration form.

11. (Amended) A method for the treatment of allergic rhinitis and rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration.

**REMARKS**

Entry of the foregoing amendments are respectfully requested.

Should the Examiner have any questions concerning the subject application, a telephone call to the undersigned would be appreciated.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: 

Teresa Stanek Rea  
Registration No. 30,427

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

**Date: March 29, 2002**

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 9 and 11**

1. (Amended) [Pharmaceutical mixture] A pharmaceutical composition comprising an effective amount of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine.
2. (Amended) [Mixture] The composition according to claim 1, [characterized in that] wherein the antihistamine is a topically administrable antihistamine.
3. (Amended) [Mixture] The composition according to [claims] claim 1 [or 2], [characterized in that] wherein the antihistamine is azelastine and/or levocabastine.
4. (Amended) [Mixture] The composition according to [one of the above claims] claim 1, [characterized in that] wherein the pharmaceutically tolerable ester is loteprednol etabonate.
5. (Amended) [Medicament] A method for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising [as active compounds] administering to a patient in need thereof, an effective amount of loteprednol and at least one topically administrable antihistamine, [if appropriate] optionally together with customary excipients or vehicles, for simultaneous, sequential or separate administration.

**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 9 and 11**

6. (Amended) [Medicament] The method according to claim 5, [characterized in that it can be administered] wherein such administration is intranasally or intraocularly simultaneously, in succession or independently of one another.

7. (Amended) [Medicament] The method according to [claims] claim 5 [or 6], [characterized in that it is] which is administered as an inhalable liquid or solid preparation.

8. (Amended) [Medicament] The method according to claim 5, [characterized in that the antihistamine can also be] which is administered orally.

9. (Amended) [Process for the preparation of a medicament] A method for the treatment and prophylaxis of airway disorders and/or allergies, comprising [as active compounds] administering to a patient in need thereof, an effective amount of loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine, [characterized in that] wherein the loteprednol or a pharmaceutically tolerable ester thereof and the antihistamine(s) are mixed individually or together, optionally together with customary excipients or vehicles, and the mixture [thus obtained is converted into] is in a suitable administration [forms] form.



**Attachment to Preliminary Amendment dated March 29, 2002**

**Marked-up Claims 1 - 9 and 11**

11. (Amended) [Use of a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration for the production of a medicament] A method for the treatment of allergic rhinitis and rhinoconjunctivitis comprising administering to a patient in need thereof, a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration.

10/089436

The present invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one antihistamine, such as, for example, azelastine and/or levocabastine, for simultaneous, sequential or separate administration in the local treatment of allergies and airway disorders, for example of allergic rhinitis (rhinoconjunctivitis).

The number of allergic disorders is increasing greatly worldwide. Studies have shown that on average 7.5% of all children and adolescents worldwide suffer from rhinoconjunctivitis (hay fever combined with an ocular symptomatology) (Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis and atopic eczema: ISAAC, Lancet, 351, 1225-1332, 1998). In West European countries, the prevalence, at about 14%, is markedly higher (Annesi-Maesano I. and Oryszczyn MP.: Rhinitis in adolescents, Results of the ISAAC survey, Revue Française d'Allergologie et d'Immunologie Clinique, 38, 283-289, 1998; Norrman E., Nystrom L, Jonsson E and Stjernberg N: Prevalence and incidence of asthma and rhinoconjunctivitis in Swedish teenagers, European Journal of Allergy and Clinical Immunology, 53, 28-35, 1998). Despite intensive research activity, the pathogenesis of rhinoconjunctivitis has still not been completely clarified. Even if marked advances in the medicinal treatment of this disorder have been achieved in the past years, the therapy is still not satisfactory. The acute symptoms (itching, reddening, swelling, rhinorrhea and lacrimation) of rhinoconjunctivitis can be readily controlled, inter alia with the aid of antihistamines. However, they barely have a therapeutically relevant influence on the inflammation which underlies the disorder and is always

progressive. Often, allergic rhinitis (rhinoconjunctivitis) is regarded both by patients and by the physician as a trivial disorder and accordingly is only inadequately treated. As a result, however, a  
5 so-called change of stage can occur, i.e. bronchial asthma, which is to be taken very seriously, develops from the relatively harmless rhinitis. For this reason, it is indispensable to treat even allergic rhinoconjunctivitis adequately and intensively. Only  
10 then can the patients live symptom-free and only then can a change of stage, which under certain circumstances is life-threatening, be prevented.

Frequently, it cannot be established by the treating  
15 physician in borderline cases with absolute certainty whether "only" rhinoconjunctivitis is still present or whether an airway disorder, such as bronchial asthma, is already present. It is advantageous if the combination according to the invention can also be  
20 employed for the treatment of disorders of the upper and lower airways.

At the present time, the corticosteroids are most effectively able to control the inflammation underlying  
25 the rhinoconjunctivitis. Many patients, but also physicians, however, do not employ these medicaments at all or only very hesitantly, usually only in a late phase of the disorder, because of their possible systemic side effects (e.g. slowdown in growth,  
30 osteoporosis).

Loteprednol belongs to the so-called "soft" steroids. Unlike other corticosteroids, which are usually only broken down in the liver to give pharmacodynamically  
35 inactive metabolites, in the case of the soft steroids the metabolic inactivation partly already takes place at the site of their administration (intranasal, ocular or intrapulmonary). As a result of this partial local metabolization, no or only very little pharmaco-

dynamically active substance reaches the systemic blood circulation, so that the steroid-specific side effects virtually do not have to be reckoned with. Loteprednol is already licensed for the therapy of allergic conjunctivitis and uveitis.

Antihistamines are employed in the acute phase of allergic rhinoconjunctivitis for the alleviation of the often irritating symptoms. The topical application of these medicaments is particularly advantageous, as high local concentrations of the active compound can be broken down in this way without having to reckon with appreciable side effects. At the current time, two locally administrable antihistamines, azelastine and levocabastine, are on the market. Both are highly efficacious and very highly tolerable.

Surprisingly, it has now been found that the novel combination of a soft steroid and at least one antihistamine is advantageous in the treatment of allergies and/or airway disorders by topical administration. Administration can in this case be carried out simultaneously, sequentially or separately. The invention serves to improve the therapy of allergic rhinitis (rhinoconjunctivitis). The antihistamine provides for the rapid elimination of the acute symptoms (e.g. reddening, itching, swelling). Using the corticosteroid contained in the combination, the inflammation underlying the condition can be successfully controlled.

According to one embodiment of the invention, loteprednol and its pharmaceutically acceptable esters, in particular loteprednol etabonate, is a particularly suitable soft steroid. The preparation of loteprednol and loteprednol etabonate is described, for example, in German Patent No. DE 31 26 732, the corresponding US Patent No. 4,996,335 and the corresponding Japanese Patent No. JP-89 011 037.

Further suitable soft steroids according to the invention are described, for example, in German Patent No. 37 86 174, the corresponding European Patent No. EP  
5 0 334 853 and the corresponding US Patent No. 4,710,495.

Azelastine and levocabastine can also be used in the form of the pharmaceutically tolerable salts. The  
10 hydrochlorides, for example, are preferred.

By means of the topical administration of the components (steroid and antihistamine), therapeutically efficacious concentrations can be achieved even at low  
15 doses. The combined administration of both substances (antihistamine + loteprednol) makes possible the control of the troublesome early-phase reactions such as itching, rhinorrhea by the antihistamine and the progress of the inflammation by the loteprednol.  
20 Moreover, the danger of the occurrence of undesired effects is thereby reduced to a minimum and better compliance of the patients is thus to be expected.

The present invention describes a novel combination, in  
25 which a soft steroid (preferably loteprednol) and an antihistamine (preferably azelastine and/or levocabastine) are given topically (intranasally or intraocularly) simultaneously, one after the other as individual substances or as a fixed combination. As a  
30 result of this combination, not only a rapid onset of action occurs but also a high therapeutic efficacy is achieved, which is accompanied by a strong antiinflammatory action. In one advantageous embodiment, the active components<sup>s</sup> of this  
35 combination are present in the form of a fixed combination, owing to which the administration is simpler for the patients, since both active compounds are contained in one and the same container.

According to a further embodiment of the invention, the antihistamine can also be administered orally.

The intended dosage is carried out twice daily, the individual dose of the soft steroid (loteprednol) being between 10 and 500 µg, preferably 50 and 200 µg. The dose of antihistamine is 50 - 500 µg, preferably 100 - 200 µg. The actual dose depends on the general condition of the patients (age, weight, etc.) and the degree of severity of the disorder.

The following pharmacological investigation was carried out in order to support the invention described.

*In vitro*, investigations on the influencing of the release of the proinflammatory cytokine TNFα in human blood of various donors diluted 1:5 were carried out. The stimulation was effected using lipopolysaccharide (LPS) from *Salmonella abortus equi* (10 µg/ml) over the course of 24 h at 37°C and 5% CO<sub>2</sub> in an incubator. The TNFα release was determined using an ELISA, based on antibodies from Pharmingen. The results were indicated as the percentage inhibition of the LPS-induced TNFα release and are shown in Table 1.

Table 1

Active compound	Concentration [µmol/l]	Inhibition of TNFα release
Azelastine	10	2%
Loteprednol	0.001	1%
	0.01	2%
	0.03	8%
Azelastine + loteprednol	10 + 0.001	12%*
	10 + 0.01	18%*
	10 + 0.03	22%*

\* significant (p<0.05)

If the antihistamine azelastine or the soft steroid loteprednol is administered alone, the LPS-induced TNFα

release remains virtually unchanged. In the presence of azelastine (10  $\mu\text{mol/l}$ ) the  $\text{TNF}\alpha$  release is inhibited to an increased extent by loteprednol in a concentration-dependent manner.

5

In vivo investigations were carried out on young domestic pigs actively sensitized with an antigen (extract from *Ascaris suum*). Three weeks later, they were exposed to allergen challenge, which was carried out by intranasal instillation of the *Ascaris* extract. This local intranasal allergen challenge leads to a very great increase in the nasal secretion (rhinorrhea). The amount of secretion was determined gravimetrically. The results are compiled in Table 2.

15

Table 2

Active compound	Dose in $\mu\text{g/nosril}$	Inhibition of nasal secretion	Number of animals
Azelastine	10	15%	5
Loteprednol	20	8%	5
Azelastine + loteprednol	10 + 20	48%*	5

\* significant ( $p < 0.05$ )

20 If the antihistamine azelastine or the soft steroid loteprednol is used at the dosages 10 or 20  $\mu\text{g/nosril}$ , only marginal inhibition of the allergically induced nasal hypersecretion occurs. If both active compounds are given at the same time, however, the rhinorrhoea is  
25 (significantly) reduced by 48%.

Various pharmaceutical formulations, e.g. nasal sprays, nasal drops and eye drops, are suitable for topical application.

30

The present invention describes a combination in which a soft steroid, e.g. loteprednol, and an antihistamine, e.g. azelastine and/or levocabastine, are administered

simultaneously, one after the other as individual substances or as a fixed combination.

On account of the water solubility of the active compound azelastine hydrochloride, formulations containing this active compound can preferably be formulated as solutions. Loteprednol etabonate, however, is virtually water-insoluble and is therefore formulated as an aqueous suspension. In a formulation in which both active compounds are combined, azelastine hydrochloride is accordingly present dissolved in water and loteprednol etabonate suspended in water.

In addition to the active constituents antihistamine, e.g. azelastine hydrochloride, and soft steroid, e.g. loteprednol etabonate, the pharmaceutical preparations according to the invention can contain further constituents such as preservatives, stabilizers, isotonicizing agents, thickeners, suspension stabilizers, excipients for pH adjustment, buffer systems and wetting agents.

Examples of suitable preservatives are: benzalkonium chloride, chlorobutanol, thiomersal, methylparaben, propylparaben, sorbic acid and its salts, sodium edetate, phenylethyl alcohol, chlorhexidine hydrochloride acetate and digluconate, cetylpyridinium chloride and bromide, chlorocresol, phenylmercury acetate, phenylmercury nitrate, phenylmercury borate, phenoxyethanol.

For preservation, the combination of sodium edetate and benzalkonium chloride is preferably used. Sodium edetate is employed here in concentrations of 0.05 - 0.1% and benzalkonium chloride in concentrations of 0.005 - 0.05%. The combination of sodium edetate, benzalkonium chloride and phenylethyl alcohol is also preferably employed.



Suitable excipients for the adjustment of the isotonicity of the formulations are, for example: sodium chloride, potassium chloride, mannitol, glucose, sorbitol, glycerol, propylene glycol. In general, these  
5 excipients are employed in concentrations from 0.1 to 10%.

The formulations of the invention can also include suitable buffer systems or other excipients for pH  
10 adjustment in order to establish and maintain a pH of the order of magnitude of 4-8, preferably of 5 to 7.5. Suitable buffer systems are citrate, phosphate, tromethamol glycine, borate, acetate. These buffer systems can be prepared from substances such as,  
15 citric acid, monosodium phosphate, disodium phosphate, glycine, boric acid, sodium tetraborate, acetic acid, sodium acetate.  
Further excipients can also be used for pH adjustment, such as hydrochloric acid or sodium hydroxide.

20 In order to prepare a stable aqueous suspension containing the water-insoluble active compound loteprednol etabonate, suitable suspension stabilizers and suitable wetting agents are furthermore necessary  
25 in order to disperse and to stabilize the suspended active compound in a suitable manner.

Suitable suspension stabilizers are water-soluble or partly water-soluble polymers: these include, for  
30 example, methylcellulose (MC), sodium carboxymethylcellulose (Na-CMC), hydroxypropylmethylcellulose (HPMC) polyvinyl alcohol (PVAL [sic]), polyvinylpyrrolidone (PVP), polyacrylic acid, polyacrylamide, gellan gum (Gelrite®) hydrated alumina (Unemul®) dextrans,  
35 cyclodextrins, and mixtures of Microcrystalline cellulose and sodium carboxymethylcellulose (Avicel RC 501®, Avicel RC 581®, Avicel RC 591®, Avicel CL 611®). These substances can simultaneously serve as thickeners in order to increase the viscosity and thereby to

prolong the contact of the active compounds with the tissue at the application site.

Suitable wetting agents for the formulations are:

- 5 benzalkonium chloride, cetylpyridinium chloride, tyloxapol, various polysorbates (Tween®), and further polyethoxylated substances and poloxamers.

Examples:

- 10 The following examples illustrate the invention without restricting it.

Example 1:

Nasal spray containing azelastine hydrochloride (0.1%)

15

Azelastine hydrochloride	0.1000 g
Hydroxypropylmethylcellulose	0.1000 g
Sodium edetate	0.0500 g
Benzalkonium chloride	0.0125 g
Sodium hydroxyde	q.s. ph 6.0
Sorbitol solution 70%	6.6666 g
Purified water	to 100 ml

Preparation of the solution:

- 20 Introduce about 45 kg of purified water into a suitable stirrer container. Add the active compound, hydroxypropylmethylcellulose, sodium edetate, benzalkonium chloride and sorbitol solution to this in succession and dissolve with stirring. Make up the resulting solution to a volume of 49.5 liters with
- 25 purified water. Adjust the pH of the solution to pH 6.0 using 1N sodium hydroxide solution. Make up to the final volume of 50.0 liters using purified water and Stir. Filter the solution through a suitable filter and dispense into bottles which are then provided with a
- 30 suitable nasal spray pump.

Example 2:

Nasal spray suspension containing loteprednol etabonate (1%)

Loteprednol etabonate	1.0000 g
Avicel RC 591	1.1000 g
Polysorbate 80	0.1000 g
Sorbitol solution 70%	6.0000 g
Sodium edetate	0.0500 g
Benzalkonium chloride	0.0200 g
Purified water	to 100 ml

5

Preparation:

10 Introduce 45 kg of purified water into a suitable stirrer container with a homogenization device and homogenize Avicel RC 591 therein at high speed. Then dissolve the substances polysorbate 80, sorbitol solution, sodium edetate and benzalkonium chloride in succession with stirring. Then homogenize the active compound loteprednol etabonate at high speed until a uniform suspension is formed. Then make up to the final volume of 50 liters with purified water and homogenize further. Then evacuate the suspension in order to remove the resulting air bubbles. The resulting suspension is then dispensed into bottles which are then provided with a suitable nasal spray pump.

20

Example 3:

25 Nasal spray containing loteprednol etabonate (1%, suspended) and azelastine hydrochloride (0.1%, dissolved)

Loteprednol etabonate	1.0000 g
Azelastine hydrochloride	0.1000 g
Avicel RC 591	1.1000 g
Polysorbate 80	0.1000 g
Sorbitol solution 70%	6.0000 g
Sodium edetate	0.0500 g
Benzalkonium chloride	0.0200 g
Purified water	to 100 ml

Preparation:

5 Introduce 45 kg of purified water into a suitable  
stirrer container with a homogenization device and  
homogenize Avicel RC 591 therein at high speed. Then  
dissolve the active compound azelastine hydrochloride  
and the excipients polysorbate 80, sorbitol solution,  
10 sodium edetate and benzalkonium chloride in succession  
with stirring.

Then homogenize the active compound loteprednol  
etabonate at high speed until a uniform suspension is  
formed. Then make up to the final volume of 50 liters  
15 with purified water and homogenize further. Then  
evacuate the suspension in order to remove the  
resulting air bubbles.

The resulting suspension is then dispensed into bottles  
which are then provided with a suitable nasal spray  
20 pump.

IC10 Rec'd PCT/PTO 29 MAR 2002

PCT/EP00/09391

Patent claims

1. Pharmaceutical mixture comprising loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine.
2. Mixture according to claim 1, characterized in that the antihistamine is a topically administrable antihistamine.
3. Mixture according to claims 1 or 2, characterized in that the antihistamine is azelastine and/or levocabastine.
4. Mixture according to one of the above claims, characterized in that the pharmaceutically tolerable ester is loteprednol etabonate.
5. Medicament for the treatment of disorders of the lower and/or upper airways and/or for the treatment of allergies, comprising as active compounds loteprednol and at least one topically administrable antihistamine, if appropriate together with customary excipients or vehicles, for simultaneous, sequential or separate administration.
6. Medicament according to claim 5, characterized in that it can be administered intranasally or intraocularly simultaneously, in succession or independently of one another.
7. Medicament according to claims 5 or 6, characterized in that it is an inhalable liquid or solid preparation.

8. Medicament according to claim 5, characterized in that the antihistamine can also be administered orally.

9. Process for the production of a medicament for the treatment and prophylaxis of airway disorders and/or allergies, comprising as active compounds loteprednol or a pharmaceutically tolerable ester thereof and at least one antihistamine, characterized in that the loteprednol or a pharmaceutically tolerable ester thereof and the antihistamine(s) are mixed individually or together, optionally together with customary excipients or vehicles, and the mixture thus obtained is converted into suitable administration forms.

10. Use of a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration for the production of a medicament for the treatment and prophylaxis of airway disorders and/or allergies.

11. Use of a combination of loteprednol or a pharmaceutically tolerable ester thereof and an antihistamine for simultaneous, sequential or separate administration for the production of a medicament for the treatment of allergic rhinitis and rhinoconjunctivitis.

9389

**Abstract**

The present invention relates to a novel combination of a soft steroid, in particular loteprednol, and at least one antihistamine, such as, for example, azelastine and/or levocabastine, for simultaneous, sequential or separate administration in the local treatment of allergies and airway disorders, for example of allergic rhinitis (rhinoconjunctivitis).

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY OR DESIGN PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**NOVEL COMBINATION OF LOTEPREDNOL AND ANTIHISTAMINES**

the specification of which (check only one item below):

- ☐ is attached hereto.
- ☐ was filed as United States application  
Number \_\_\_\_\_ on \_\_\_\_\_  
and was amended \_\_\_\_\_ (if applicable).
- ☒ was filed as PCT international application  
Number PCT/EP00/09391 on 26 SEPTEMBER 2000  
and was amended \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §§119 (a)-(d), 172 or 365 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §§119(a)-(d), 172 or 365:				
COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §§119, 172 or 365	
GERMANY	199 47 234.3	30 SEPTEMBER 1999	X Yes	No
			Yes	No
			Yes	No
			Yes	No
			Yes	No



Combined Declaration and Power of Attorney  
for Utility or Design Patent Application  
Attorney's Docket No. 033285-009  
Page 2 of 3

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Welsblat	30,505	Bruce T. Wieder	33,815
Robert S. Swecker	19,885	James W. Peterson	26,057	Todd R. Walters	34,040
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427	Ronni S. Jillions	31,979
Benton S. Duffett, Jr.	22,030	Robert E. Krebs	25,885	Harold R. Brown III	36,341
Norman H. Stepno	22,716	William C. Rowland	30,888	Allen R. Baum	36,086
Ronald L. Grudziecki	24,970	T. Gene Dillahunty	25,423	Brian P. O'Shaughnessy	32,747
Frederick G. Michaud, Jr.	26,003	Patrick C. Keane	32,858	Kenneth B. Leffler	36,075
Alan E. Kopecki	25,813	B. Jefferson Boggs, Jr.	32,344	Fred W. Hathaway	32,236
Regis E. Slutter	26,999	William H. Benz	25,952	Wendi L. Weinstein	34,456
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917	Mary Ann Dillahunty	34,576
Robert G. Mukai	28,531	Richard J. McGrath	29,195	Donna M. Mcuth	36,607
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814	Mark R. Kresloff	42,766
James A. LaBarre	28,632	Michael G. Savage	32,596		
E. Joseph Gess	28,510	Gerald F. Swiss	30,113		
R. Danny Huntington	27,903	Charles F. Wieland III	33,096		

  
**21839**

and:

Address all correspondence to:


TERESA STANEK REA, ESQ.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404



**21839**

Address all telephone calls to: Teresa Stanek Rea (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>FULL NAME OF SOLE OR FIRST INVENTOR</b>	Istvan SZELENYI
Signature	
Date	12/22/02
Residence (City, State, Country)	Schwaig, DEUTSCHLAND DEX
Citizenship	GERMANY
Mailing Address	Haendelstrasse 32, 90571 Schwaig, DEUTSCHLAND
City, State, ZIP, Country	90571 Schwaig, DEUTSCHLAND
<b>FULL NAME SECOND INVENTOR, IF ANY</b>	Degenhard MARX
Signature	
Date	
Residence (City, State, Country)	Radebeul, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Gradsteg 16, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND

<b>FULL NAME THIRD INVENTOR, IF ANY</b>	Sabine HEER
Signature	X
Date	X
Residence (City, State, Country)	Radebeul, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Lindenauer Strasse 13, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND
<b>FULL NAME FOURTH INVENTOR, IF ANY</b>	Juergen ENGEL
Signature	X
Date	X
Residence (City, State, Country)	Alzenau, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Erlenweg 3, 63755 Alzenau, DEUTSCHLAND
City, State, ZIP, Country	63755 Alzenau, DEUTSCHLAND
<b>FULL NAME FIFTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SIXTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SEVENTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY OR DESIGN PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL COMBINATION OF LOTEPREDNOL AND ANTIHISTAMINES

the specification of which (check only one item below):

- ☐ is attached hereto.
- ☐ was filed as United States application  
Number \_\_\_\_\_ on \_\_\_\_\_  
and was amended \_\_\_\_\_ on \_\_\_\_\_ (if applicable).
- ☒ was filed as PCT international application  
Number PCT/EP00/09391 on 26 SEPTEMBER 2000  
and was amended \_\_\_\_\_ on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §§119 (a)-(d), 172 or 365 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §119(a)-(d), 172 or 365:					
COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §119, 172 or 365		
GERMANY	199 47 234.3	30 SEPTEMBER 1999	X	Yes	No
				Yes	No
				Yes	No
				Yes	No
				Yes	No

Combined Declaration and Power of Attorney  
for Utility or Design Patent Application  
Attorney's Docket No. 033285-009  
Page 2 of 3

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Welsblat	30,505	Bruce T. Wieder	33,815
Robert S. Swecker	19,885	James W. Peterson	26,057	Todd R. Walters	34,040
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427	Ronni S. Jillions	31,979
Benton S. Duffett, Jr.	22,030	Robert E. Krebs	25,885	Harold R. Brown III	36,341
Norman H. Stepno	22,716	William C. Rowland	30,888	Allen R. Baum	36,086
Ronald L. Grudziecki	24,970	T. Gene Dillahunt	25,423	Brian P. O'Shaughnessy	32,747
Frederick G. Michaud, Jr.	26,003	Patrick C. Keane	32,858	Kenneth B. Leffler	36,075
Alun E. Kopceki	25,813	B. Jefferson Boggs, Jr.	32,344	Fred W. Hathaway	32,236
Regis E. Slutter	26,999	William H. Benz	25,952	Wendi L. Weinstein	34,456
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917	Mary Ann Dillahunt	34,576
Robert G. Mukai	28,531	Richard J. McGrath	29,195	Donna M. Meuth	36,607
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814	Mark R. Kresloff	42,766
James A. LaBarre	28,632	Michael G. Savage	32,596		
E. Joseph Gess	28,510	Gerald F. Swiss	30,113		
R. Danny Huntington	27,903	Charles F. Wieland III	33,096		

  
21839

and:

Address all correspondence to:



21839

TERESA STANEK REA, ESQ.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: Teresa Stanek Rea (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>FULL NAME OF SOLE OR FIRST INVENTOR</b>	Istvan SZELENYI
Signature	X
Date	/
Residence (City, State, Country)	Schwaig, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Haendelstrasse 32, 90571 Schwaig, DEUTSCHLAND
City, State, ZIP, Country	90571 Schwaig, DEUTSCHLAND
<b>FULL NAME SECOND INVENTOR, IF ANY</b>	Degenhard MARX
Signature	<i>Degenhard Marx</i>
Date	25.05.02
Residence (City, State, Country)	Radebeul, DEUTSCHLAND DEX
Citizenship	GERMANY
Mailing Address	Gradsteg 16, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND

Combined Declaration and Power of Attorney  
for Utility or Design Patent Application  
Attorney's Docket No. 033285-009  
Page 3 of 3

<b>FULL NAME THIRD INVENTOR, IF ANY</b>	Sabine HEER
Signature	X
Date	✓
Residence (City, State, Country)	Radebeul, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Lindenauer Strasse 13, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND
<b>FULL NAME FOURTH INVENTOR, IF ANY</b>	Juergen ENGEL
Signature	X
Date	✓
Residence (City, State, Country)	Alzenau, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Erlenweg 3, 63755 Alzenau, DEUTSCHLAND
City, State, ZIP, Country	63755 Alzenau, DEUTSCHLAND
<b>FULL NAME FIFTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SIXTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SEVENTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	

**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY OR DESIGN PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**NOVEL COMBINATION OF LOTEPREDNOL AND ANTIHISTAMINES**

the specification of which (check only one item below):

- ☐ is attached hereto.
- ☐ was filed as United States application  
Number \_\_\_\_\_ on \_\_\_\_\_  
and was amended \_\_\_\_\_ on \_\_\_\_\_ (if applicable).
- ☒ was filed as PCT international application  
Number PCT/EP00/09391 on 26 SEPTEMBER 2000  
and was amended \_\_\_\_\_ on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §§119 (a)-(d), 172 or 365 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §§119(a)-(d), 172 or 365:				
COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §§119, 172 or 365	
GERMANY	199 47 234.3	30 SEPTEMBER 1999	X Yes	No
			Yes	No
			Yes	No
			Yes	No
			Yes	No

Combined Declaration and Power of Attorney  
for Utility or Design Patent Application  
Attorney's Docket No. 033285-009  
Page 2 of 3

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Welsblat	30,505	Bruce T. Wieder	33,815
Robert S. Swecker	19,885	James W. Peterson	26,057	Todd R. Walters	34,040
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427	Ronni S. Jillions	31,979
Benton S. Duffett, Jr.	22,030	Robert E. Krebs	25,883	Harold R. Brown III	36,341
Norman H. Szepno	22,716	William C. Rowland	30,888	Allen R. Baum	36,086
Ronald L. Grudzicki	24,970	T. Gene Dillahunty	25,423	Brian P. O'Shaughnessy	32,747
Frederick G. Michaud, Jr.	26,003	Patrick C. Keane	32,858	Kenneth B. Leffler	36,075
Alan E. Kopecki	25,813	B. Jefferson Boggs, Jr.	32,344	Fred W. Hathaway	32,236
Regis E. Slutter	26,999	William H. Benz	25,952	Wendi L. Weinstein	34,456
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917	Mary Ann Dillahunty	34,576
Robert G. Mukai	28,531	Richard J. McGrath	29,195	Donna M. Meuth	36,607
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814	Mark R. Kresloff	42,766
James A. LaBarre	28,632	Michael G. Savage	32,596		
E. Joseph Gess	28,510	Gerald F. Swiss	30,113		
R. Danny Huntington	27,903	Charles F. Wieland III	33,096		

  
21839

and:

Address all correspondence to:







21839

TERESA STANEK REA, ESQ.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: Teresa Stanek Rea (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>FULL NAME OF SOLE OR FIRST INVENTOR</b>	Istvan SZELENYI
Signature	
Date	
Residence (City, State, Country)	Schwaig, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Haendelstrasse 32, 90571 Schwaig, DEUTSCHLAND
City, State, ZIP, Country	90571 Schwaig, DEUTSCHLAND
<b>FULL NAME SECOND INVENTOR, IF ANY</b>	Degenhard MARX
Signature	
Date	
Residence (City, State, Country)	Radebeul, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Gradsteg 16, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND

3-00

<b>FULL NAME THIRD INVENTOR, IF ANY</b>	Sabine HEER
Signature	X <i>Sabine Heer</i>
Date	X 10.06.2002
Residence (City, State, Country)	Radebeul, DEUTSCHLAND <i>DEX</i>
Citizenship	GERMANY
Mailing Address	Lindenauer Strasse 13, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND
<b>FULL NAME FOURTH INVENTOR, IF ANY</b>	Juergen ENGEL
Signature	X
Date	X
Residence (City, State, Country)	Alzenau, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Erlenweg 3, 63755 Alzenau, DEUTSCHLAND
City, State, ZIP, Country	63755 Alzenau, DEUTSCHLAND
<b>FULL NAME FIFTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SIXTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SEVENTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	



**COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR UTILITY OR DESIGN PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**NOVEL COMBINATION OF LOTEPREDNOL AND ANTIHISTAMINES**

the specification of which (check only one item below):

- ☐ is attached hereto.
- ☐ was filed as United States application  
Number \_\_\_\_\_ on \_\_\_\_\_  
and was amended \_\_\_\_\_ on \_\_\_\_\_ (if applicable).
- ☒ was filed as PCT international application  
Number PCT/EP00/09391 on 26 SEPTEMBER 2000  
and was amended \_\_\_\_\_ on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, §§119 (a)-(d), 172 or 365 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S) AND ANY PRIORITY CLAIMS UNDER 35 U.S.C. §§119(a)-(d), 172 or 365:				
COUNTRY (if PCT, indicate "PCT")	APPLICATION NUMBER	DATE OF FILING (day, month, year)	PRIORITY CLAIMED UNDER 35 U.S.C. §§119, 172 or 365	
GERMANY	199 47 234.3	30 SEPTEMBER 1999	X Yes	No
			Yes	No
			Yes	No
			Yes	No
			Yes	No

Combined Declaration and Power of Attorney  
for Utility or Design Patent Application  
Attorney's Docket No. 033285-009  
Page 2 of 3

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Welsblat	30,505	Bruce T. Wieder	33,815
Robert S. Swecker	19,885	James W. Peterson	26,057	Todd R. Walters	34,040
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427	Ronni S. Jillions	31,979
Bernon S. Duffett, Jr.	22,030	Robert E. Krebs	25,885	Harold R. Brown III	36,341
Norman H. Stepno	22,716	William C. Rowland	30,888	Allen R. Baum	36,086
Ronald L. Grudziecki	24,970	T. Gene Dillahunty	25,423	Brian P. O'Shaughnessy	32,747
Frederick G. Michaud, Jr.	26,003	Patrick C. Kcane	32,858	Kenneth B. Leffler	36,075
Alan E. Kopecki	25,813	B. Jefferson Boggs, Jr.	32,344	Fred W. Hathaway	32,236
Regis E. Slutter	26,999	William H. Benz	25,952	Wendi L. Weinstein	34,456
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917	Mary Ann Dillahunty	34,576
Robert G. Mukai	28,531	Richard J. McGrath	29,195	Donna M. Meuth	36,607
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814	Mark R. Kresloff	42,766
James A. LaBarre	28,632	Michael G. Savage	32,596		
E. Joseph Gess	28,510	Gerald F. Swiss	30,113		
R. Danny Huntington	27,903	Charles F. Wieland III	33,096		



21839

and:

Address all correspondence to:



21839

TERESA STANEK REA, ESQ.  
BURNS, DOANE, SWECKER & MATHIS, L.L.P.  
P.O. Box 1404  
Alexandria, Virginia 22313-1404

Address all telephone calls to: Teresa Stanek Rea (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

<b>FULL NAME OF SOLE OR FIRST INVENTOR</b>	Istvan SZELENYI
Signature	X
Date	X
Residence (City, State, Country)	Schwaig, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Haendelstrasse 32, 90571 Schwaig, DEUTSCHLAND
City, State, ZIP, Country	90571 Schwaig, DEUTSCHLAND
<b>FULL NAME SECOND INVENTOR, IF ANY</b>	Degenhard MARX
Signature	X
Date	X
Residence (City, State, Country)	Radebeul, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Gradsteg 16, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND

Combined Declaration and Power of Attorney  
for Utility or Design Patent Application  
Attorney's Docket No. 033285-009  
Page 3 of 3

<b>FULL NAME THIRD INVENTOR, IF ANY</b>	Sabine HEER
Signature	X
Date	✓
Residence (City, State, Country)	Radebeul, DEUTSCHLAND
Citizenship	GERMANY
Mailing Address	Lindenauer Strasse 13, 01445 Radebeul, DEUTSCHLAND
City, State, ZIP, Country	01445 Radebeul, DEUTSCHLAND
<b>FULL NAME FOURTH INVENTOR, IF ANY</b>	Juergen ENGEL
Signature	<i>[Signature]</i>
Date	May 23, 2002
Residence (City, State, Country)	Alzenau, DEUTSCHLAND DEX
Citizenship	GERMANY
Mailing Address	Erlenweg 3, 63755 Alzenau, DEUTSCHLAND
City, State, ZIP, Country	63755 Alzenau, DEUTSCHLAND
<b>FULL NAME FIFTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SIXTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	
<b>FULL NAME SEVENTH INVENTOR, IF ANY</b>	
Signature	
Date	
Residence (City, State, Country)	
Citizenship	
Mailing Address	
City, State, ZIP, Country	